NCT05858047已完成2 期
A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 93
- 试验地点
- 1
- 主要终点
- Percentage of Participants Achieving a Psoriasis Area and Severity Index Score ≥75% (PASI 75) response
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis in order to select doses for further clinical trials.
详细描述
This is a multicenter, randomized, double-blind, placebo-controlled phase Ⅱ study to evaluate the efficacy and safety of three different doses of SYHX1901 tablets compared with placebo in the treatment of moderate to severe plaque psoriasis. The total duration of the study will be 20 weeks which will be comprised of: a screening period (4 weeks); an efficacy assessment period (12 weeks) and a follow-up assessment period (4 weeks). Eligible subjects will be randomly assigned to SYHX1901 60 mg qd, 90 mg qd, 180 mg qd or placebo group at a 1:1:1:1 ratio for continuous oral administration for 12 weeks. The presence or absence of treatment with biological agents will be a stratification factor. Subjects will be monitored for the safety throughout the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects fully understand and voluntarily participate in this study and sign informed consent;
- •Age ≥18 and ≤ 75 years old;
- •Subjects with a clinical diagnosis of stable moderate-to-severe plaque psoriasis with a history ≥6 months before randomization; Subjects with stable moderate-to-severe plaque psoriasis defined as meeting all four of the following criteria simultaneously:
- •Subject must be diagnosed of chronic plaque psoriasis with no morphological changes or significant outbreaks of disease activity assessed by the investigator;
- •Subject must be a candidate for systemic treatment or phototherapy assessed by the investigator;
- •Body Surface Area (BSA) affected by plaque-type psoriasis ≥10% at screening and baseline;
- •PASI score of ≥12 and Physician's Global Assessment (PGA) score ≥3 at screening and baseline;
- •Negative blood pregnancy results should be provided 14 days (inclusive) and 3 days (inclusive) prior to initial dosing, and subjects and their partners should voluntarily take contraceptive measures considered effective by the investigator during the study period and for at least 28 days after the study;
- •Subjects must be volunteer and be able to complete study procedures and follow-up examinations.
排除标准
- •Forms of psoriasis other than plaque psoriasis (Guttate psoriasis、erythrodermic psoriasis、Pustular psoriasis、Drug-induced psoriasis);
- •Previous or current autoimmune disease;
- •Other active skin conditions that may affect the clinical evaluation of psoriasis;
- •Active infection or fever at randomization;
- •Severe bacterial, fungal, or viral infection requiring hospitalization/intravenous drug treatment within 60 days prior to randomization;
- •Any proven history of untreated bacterial infection within 60 days prior to randomization;
- •Any existing evidence of chronic infection;
- •Any proven history of infection of a joint prosthesis or receiving antibiotics for a suspected joint prosthesis infection;
- •Received live vaccine within 60 days before randomization or scheduled to receive live vaccine within 60 days after the end of the study;
- •History of severe herpes zoster or sever herpes simplex infection;
- •Abnormal hepatitis B virus (HBV) related check during screening;
- •Hepatitis C virus (HCV) antibody positive at screening;
- •HIV antibody or treponema pallidum antibody positive;
- •Any known or suspected condition of congenital or acquired immunodeficiency;
- •Tuberculosis (TB);
- •Symptoms or signs of progressive or uncontrolled kidney, liver, blood, gastrointestinal, endocrine, lung, heart, neurological, psychiatric, or brain disease, or with other chronic diseases that the investigator has determined are not suitable for participation in this clinical trial;
- •History of malignancy or lymphoproliferative disease within 5 years (except for cured basal cell carcinoma and in situ cervical cancer);
- •Major surgery within 8 weeks before randomization or surgery planned during the study;
- •Uncontrolled hypertension, systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg after systemic treatment;
- •Having unstable cardiovascular disease defined as presence of a clinical cardiovascular event in the last 3 months or hospitalized for heart disease within the last 3 months; or NYHA≥3 grade, or abnormal ECG suggesting clinically significant and assessed by the investigator as carrying unforeseen risks;
- •History of arterial or venous thrombosis or at high risk;
- •Significant gastrointestinal disorders, such as erosion, hemorrhagic gastroenteritis, a history of bleeding from gastrointestinal ulcers, inflammatory bowel disease, and other disorders that investigator consider to be at risk for gastrointestinal perforation or that may interfere with drug ingestion, transport, or absorption;
- •Uncontrolled hyperlipidemia (TG>2.3 mmol/L and/or LDL>3.4 mmol/L) after standard treatment;
- •Low body weight (weight ≤45 kg or BMI≤18 kg/m^2);
- •BMI ≥30kg/m^2， (severe obesity);
- •Have received local anti-psoriasis therapy within 2 weeks prior to randomization; If topical moisturizers have been used within 2 weeks, they should be continued throughout the trial, with the same frequency and dose until the end of the study;
- •Have used physical therapy within 4 weeks prior to randomization (including photochemotherapy, ultraviolet therapy);
- •Systemic treatments:
- •Systemic anti-psoriasis therapy within 4 weeks before study drug initiation;
- •Leflunomide within 6 months before study drug initiation;
- •Opioid analgesics within 4 weeks before study drug initiation;
- •Lithium and antimalarial drugs within 4 weeks before study drug initiation;
- •Any CYP3A4 potent inhibitor/inducer within 4 weeks before study drug initiation;
- •Any P-gp potent inhibitor/inducer within 4 weeks before study drug initiation;
- •Thymosin administered by injection or orally within 4 weeks before study drug initiation;
- •Use of BCRP-sensitive substrate drugs assessed by the investigator during the study;
- •Biological agents:
- •Exposure to any biological drug directly targeting IL-17 or IL-12, or IL-23 within 6 months prior to randomization ;
- •Exposure to any TNF monoclonal antibody within 2 months prior to randomization;
- •Exposure to any monoclonal antibodies against CD20 within 6 months prior to randomization;
- •Exposure to any T cell or B cell modulators or integrin pathway modulators within 3 months prior to randomization;
- •Any other biological drugs within 5 half-lives before study drug initiation;
- •Enrolled in a clinical study of any other drug within 3 months or use of any other investigational drugs within 5 half-lives of the investigational treatment before randomization;
- •History of lack of response to treatment after at least 3 months of treatment with any monoclonal antibody targeting IL-17 or IL-23 at approved doses;
- •Organ transplantation (except corneal transplantation more than 3 months before the initiation of the investigational drug);
- •Impossible to avoid prolonged daylight exposure during the trial, or to plan to use UV health rooms or other UV light sources;
- •Laboratory abnormalities of clinical significance assessed by the investigator to pose a risk:
- •AST or ALT ≥ 2×ULN;
- •Total bilirubin and/or direct bilirubin >2×ULN;
- •Neutrophil absolute value (NEUT#) <1.5×10^9/L;
- 另有 5 项未显示
研究组 & 干预措施
Group I (Placebo)
Placebo Comparator
Placebo will be administered orally (PO) for 12 weeks.
干预措施: Placebo (Drug)
Group Ⅱ (SYHX1901 60 mg)
Experimental
SYHX1901 will be administered orally (PO) for 12 weeks.
干预措施: SYHX1901 (Drug)
Group III (SYHX1901 90 mg)
Experimental
SYHX1901 will be administered orally (PO) for 12 weeks.
干预措施: SYHX1901 (Drug)
Group Ⅳ (SYHX1901 180 mg)
Experimental
SYHX1901 will be administered orally (PO) for 12 weeks.
干预措施: SYHX1901 (Drug)
结局指标
主要结局
Percentage of Participants Achieving a Psoriasis Area and Severity Index Score ≥75% (PASI 75) response
时间窗: Week 12
次要结局
- Percentage of Participants Achieving a Physician Global Assessment (PGA) of 0 or 1(Week 12)
- Percentage of Participants Achieving a Psoriasis Area and Severity Index Score ≥50% (PASI 50) response(Week 12)
- Change from Baseline in Body Surface Area (BSA) affected with Psoriasis to Week 12(Week 12)
- Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) of 0 or 1(Week 12)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
A Phase II Study of SYHX1901 Tablets in the Treatment of Severe Alopecia AreataSevere Alopecia AreataNCT06562894CSPC Ouyi Pharmaceutical Co., Ltd.156
已完成
3 期
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.Psychotic DisorderSchizoaffective DisorderNCT00397033Johnson & Johnson Pharmaceutical Research & Development, L.L.C.316
已完成
1 期
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly CohortAlzheimer's DiseaseNCT01294540Eisai Inc.73
已完成
1 期
IAMA-6 Oral Dose Study in Healthy AdultsNeurodevelopmental DisordersNCT06300398Iama Therapeutics S.r.l.72
已完成
2 期
A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in AsthmaticsAsthmaNCT01689571Chiesi Farmaceutici S.p.A.36